查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1957249

药品灌装和包装契约製造市场－全球产业规模、份额、趋势、机会和预测：按产品类型、分子类型、最终用户、地区和竞争格局划分，2021-2031年

Fill-finish Pharmaceutical Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By Molecule Type, By End-user, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球灌装和包装药品的契约製造市场预计将从 2025 年的 86.1 亿美元成长到 2031 年的 123.2 亿美元，复合年增长率为 6.15%。

该行业细分领域涵盖最终生产阶段，包括将配製好的药品填充到无菌容器（例如管瓶和注射器）中，并进行包装以供商业分销。推动成长的关键因素是全球对需要特殊无菌处理的生物製药的需求不断增长，以及製药研发公司将这些营运外包的策略转变。这种方式使公司能够避免维护无菌设施相关的高昂资本成本，并将资源集中在药物研发等核心活动，同时利用外部专业知识来完成复杂的填充流程。

市场概览
预测期 2027-2031
市场规模：2025年 86.1亿美元
市场规模：2031年 123.2亿美元
复合年增长率：2026-2031年 6.15%
成长最快的细分市场 预填充式注射器
最大的市场 亚太地区

然而，该产业在应对产能限制的同时，也必须遵守严格的无菌保证监管标准，这构成了一项重大挑战。扩大无菌生产线规模所面临的复杂挑战常常造成生产瓶颈，尤其是在高价值注射领域。根据製药、化学及相关技术协会 (DCAT) 预测，到 2025 年，该行业正积极应对这些限制，预计将有 15 亿至 20 亿美元的投资用于建设大规模灌装和包装设施，这些设施计划在不久的将来投入运作。这些数据凸显了契约製造製造商在严格遵守品质标准的同时，快速扩展基础设施的巨大压力。

市场驱动因素

该领域的成长主要受生物製药和生物相似药市场的快速扩张所驱动，尤其是对Glucagon-Like Peptide-1(GLP-1)促效剂的爆炸性需求。这些高分子量治疗药物需要高度专业化的无菌环境和温度控制，使得许多製药公司难以实现内部规模化生产，导致对契约製造的依赖性日益增强。这种依赖性已经发展到大型製药公司收购契约製造以确保其供应链安全的程度。例如，诺和诺德 (Novo Holdings) 于 2024 年 2 月宣布，已达成一项价值 165 亿美元的合併协议，收购契约製造Catalent，以确保获得三家用于糖尿病和减肥药的填充和包装工厂。这一趋势表明，生产无菌注射剂的能力正成为一项与药物研发本身同等重要的策略性资产。

同时，预填充式注射器和先进给药系统的日益普及，促使生产线进行重组，并需要发展更精湛的技术。製药研发公司正从传统的管瓶转向以患者为中心的给药方式，以减少给药错误并提高用药依从性，这迫使契约製造製造商投资建造专用的即用型组件填充线。这种向高附加价值给药系统的转变与供应商的收入成长直接相关。根据 Stevanat 集团于 2024 年 3 月发布的《2023 年第四季及全年财务业绩报告》，其年收入成长 10% 至 10.9 亿欧元，主要得益于高附加价值预灭菌容器解决方案的广泛应用。为了满足这一不断变化的需求，FUJIFILM迪奥辛塔生物技术公司等製造商正在积极扩张。 2024 年 4 月，该公司决定追加投资 12 亿美元，用于扩大其大型生物製造设施，并确保拥有足够的基础设施以进行复杂的无菌加工。

市场挑战

全球灌装包装药品的契约製造市场面临一项重大挑战：如何在严格遵守无菌通讯协定的同时，有效管理产能限制。儘管生物製药的需求不断增长，但无菌环境下复杂的验证流程使得契约製造生产商难以快速扩大生产线规模以满足市场需求。这种营运瓶颈限制了高价值注射剂的最终灌装量，迫使生产商推迟计划进度，甚至可能终止合同，从而直接限制了整体市场收入。

近期有关供应缺口的产业指标凸显了这项限制的严重性。据美国医疗保健系统药剂师协会 (ASHP) 称，2024 年第一季，医疗保健行业经历了创纪录的 323 起药品短缺事件，其中约一半与无菌注射剂相关。这些频繁的短缺表明，目前的填充和包装基础设施已不堪重负，无法持续满足商业性需求。因此，由于製造商难以调整产能以满足全球日益增长的无菌药品需求，市场成长受到阻碍。

市场趋势

无手套机器人隔离器和自动化填充线的整合正在变革无菌生产。这主要源自于产业消除人为错误并遵守欧盟GMP附录1等严格法规的需求。这些系统透过完全消除关键无菌区域的人员，显着降低了污染风险，并确保了高度敏感生物製药的更高无菌保证。契约製造製造商正积极采用这项技术，以提供更优异的合规性和营运效率。例如，根据《医疗保健包装》杂誌2024年5月刊报道，PCI Pharma Services公司在新罕布夏州启动了一项耗资1亿美元的扩建计划，其中包括安装一条最先进的大型隔离器填充线。该计划显然旨在透过从设计阶段就考虑无菌性的流程来提高高通量生产能力。

同时，市场处理高活性和细胞毒性药物的能力正在迅速扩张，这主要得益于抗体药物复合体（ADC）的復兴。与标准生物製药不同，这些治疗方法需要专门的设施，既要确保产品的无菌性，又要严格保护操作人员免受毒性物质的侵害。为此，合约研发生产机构（CDMO）正在建造专用的高等级生物安全填充和包装车间。同时，大量资金也投入专门为高活性化合物设计的基础建设。根据LiveMint 2024年9月的报告显示，Piramal Pharma Solutions宣布投资8,000万美元扩建位于莱剋星顿的工厂，旨在提升其抗体药物复合体（ADC）和其他无菌注射剂的商业化生产能力。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球药品灌装与包装契约製造市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依产品类型（预填充式注射器、管瓶、药筒、其他）
    • 依分子类型（高分子量、低分子量）
    • 依最终用户（製药和生技公司、契约製造组织等）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美药品填充和包装契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲药品灌装和包装契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区药品填充和包装契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲药品填充和包装契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲药品填充和包装契约製造市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球药品填充和包装契约製造市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Pfizer Inc.
  • Baxter Pharmaceutical Solutions LLC
  • Eurofins Scientific SE
  • Symbiosis Pharma Pvt Ltd
  • MabPlex International Co. Ltd.
  • Fresenius Kabi Manufacturing
  • Novartis AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 24057

The Global Fill-finish Pharmaceutical Contract Manufacturing Market is projected to expand from USD 8.61 Billion in 2025 to USD 12.32 Billion by 2031, registering a CAGR of 6.15%. This industry segment encompasses the final production stage where formulated medications are dispensed into sterile containers, such as vials or syringes, and packaged for commercial distribution. Growth is largely fueled by the rising global demand for biologics requiring specialized aseptic processing, coupled with a strategic shift among pharmaceutical developers to outsource these operations. This approach enables companies to avoid the high capital costs of maintaining sterile facilities, allowing them to redirect resources toward core competencies like drug discovery while utilizing external expertise for the complex finishing process.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.61 Billion
Market Size 2031USD 12.32 Billion
CAGR 2026-20316.15%
Fastest Growing SegmentPrefilled Syringes
Largest MarketAsia Pacific

However, the industry faces significant hurdles related to managing capacity limitations while adhering to strict regulatory standards for sterility assurance. The intricacies involved in scaling sterile manufacturing lines frequently result in bottlenecks, especially for high-value injectable therapies. According to the Drug, Chemical & Associated Technologies Association, in 2025, the sector actively addressed these constraints with major fill-finish investments estimated between $1.5 billion and $2 billion slated to become operational in the near future. This data underscores the intense pressure on contract manufacturers to rapidly broaden their infrastructure while strictly complying with rigorous quality standards.

Market Driver

The sector is primarily driven by the rapid growth of the biologics and biosimilars market, specifically the explosive demand for glucagon-like peptide-1 (GLP-1) receptor agonists. These large-molecule therapies necessitate highly specific aseptic environments and temperature controls that many pharmaceutical originators cannot scale internally, creating a heavy reliance on contract manufacturers. This dependency has escalated to the point where major pharmaceutical companies are acquiring contract organizations to ensure supply chain security; for instance, according to Novo Holdings' February 2024 press release regarding the acquisition of Catalent, the organization entered a merger agreement valued at $16.5 billion to acquire the contract manufacturer specifically to secure three fill-finish sites for its diabetes and obesity treatments. This trend suggests that manufacturing capacity for sterile injectables is becoming a strategic asset as vital as drug discovery itself.

Simultaneously, the increasing use of prefilled syringes and advanced delivery systems is reshaping production lines and necessitating technical specialization. Pharmaceutical developers are transitioning from traditional vials to patient-centric delivery formats that decrease dosing errors and enhance adherence, compelling contract manufacturers to invest in specialized filling lines for ready-to-use components. This shift toward high-value delivery systems translates directly into revenue growth for suppliers; according to Stevanato Group's 'Fourth Quarter and Full Year 2023 Financial Results' in March 2024, fiscal revenue rose 10% to €1.09 billion, driven largely by the surging adoption of high-value pre-sterilized containment solutions. To meet this evolving demand, manufacturers like Fujifilm Diosynth Biotechnologies are aggressively expanding, with the company committing an additional $1.2 billion in April 2024 to expand its large-scale biomanufacturing facility and ensure sufficient infrastructure for complex aseptic processing.

Market Challenge

The Global Fill-finish Pharmaceutical Contract Manufacturing Market faces a primary obstacle in managing capacity limitations while adhering to rigorous sterility protocols. Despite the rising demand for biological therapies, contract manufacturers frequently struggle to expand production lines rapidly enough to match this pace due to the complex validation processes required for aseptic environments. This operational bottleneck restricts the volume of high-value injectables that can be finalized, compelling manufacturers to delay project timelines and decline potential contracts, which directly constrains overall market revenue.

The severity of this constraint is highlighted by recent industry metrics concerning supply gaps. According to the American Society of Health-System Pharmacists, the healthcare sector recorded a historic high of 323 active drug shortages during the first quarter of 2024, with nearly half of these cases involving sterile injectable medications. This high frequency of shortages demonstrates that the current fill-finish infrastructure is critically strained and unable to consistently meet commercial requirements. Consequently, the market's growth is impeded as manufacturers struggle to align their output capabilities with the escalating global necessity for sterile drug products.

Market Trends

The integration of gloveless robotic isolators and automated filling lines is transforming sterile manufacturing, driven by the industry's need to eliminate human error and comply with stringent regulations such as EU GMP Annex 1. By completely removing operators from critical aseptic zones, these systems significantly lower contamination risks and ensure higher sterility assurance levels for sensitive biological products. Contract manufacturers are aggressively adopting this technology to provide superior compliance profiles and operational efficiency; for example, according to Healthcare Packaging in May 2024, PCI Pharma Services began installing a state-of-the-art, large-scale isolator filling line as part of a $100 million expansion in New Hampshire, explicitly aiming to increase high-throughput capacity with aseptic-by-design processes.

Concurrently, the market is observing a rapid expansion in capabilities for handling high-potency and cytotoxic drugs, particularly propelled by the resurgence of antibody-drug conjugates (ADCs). Unlike standard biologics, these therapies require specialized facilities that ensure both product sterility and rigorous operator protection from toxic exposure, prompting CDMOs to construct dedicated high-containment fill-finish suites. This trend involves significant capital allocation toward infrastructure designed specifically for highly active compounds; according to LiveMint in September 2024, Piramal Pharma Solutions announced an $80 million investment to expand its Lexington site, specifically to enhance its commercial manufacturing capabilities for antibody-drug conjugates and other sterile injectables.

Key Market Players

  • AbbVie Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Pfizer Inc.
  • Baxter Pharmaceutical Solutions LLC
  • Eurofins Scientific SE
  • Symbiosis Pharma Pvt Ltd
  • MabPlex International Co. Ltd.
  • Fresenius Kabi Manufacturing
  • Novartis AG

Report Scope

In this report, the Global Fill-finish Pharmaceutical Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fill-finish Pharmaceutical Contract Manufacturing Market, By Product Type

  • Prefilled Syringes
  • Vials
  • Cartridges
  • Others

Fill-finish Pharmaceutical Contract Manufacturing Market, By Molecule Type

  • Large Molecules
  • Small Molecules

Fill-finish Pharmaceutical Contract Manufacturing Market, By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Manufacturing Organizations
  • Others

Fill-finish Pharmaceutical Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Fill-finish Pharmaceutical Contract Manufacturing Market.

Available Customizations:

Global Fill-finish Pharmaceutical Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Prefilled Syringes, Vials, Cartridges, Others)
    • 5.2.2. By Molecule Type (Large Molecules, Small Molecules)
    • 5.2.3. By End-user (Pharmaceutical & Biotechnology Companies, Contract Manufacturing Organizations, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Molecule Type
    • 6.2.3. By End-user
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By Molecule Type
        • 6.3.1.2.3. By End-user
    • 6.3.2. Canada Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By Molecule Type
        • 6.3.2.2.3. By End-user
    • 6.3.3. Mexico Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By Molecule Type
        • 6.3.3.2.3. By End-user

7. Europe Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Molecule Type
    • 7.2.3. By End-user
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By Molecule Type
        • 7.3.1.2.3. By End-user
    • 7.3.2. France Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By Molecule Type
        • 7.3.2.2.3. By End-user
    • 7.3.3. United Kingdom Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By Molecule Type
        • 7.3.3.2.3. By End-user
    • 7.3.4. Italy Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By Molecule Type
        • 7.3.4.2.3. By End-user
    • 7.3.5. Spain Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By Molecule Type
        • 7.3.5.2.3. By End-user

8. Asia Pacific Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Molecule Type
    • 8.2.3. By End-user
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By Molecule Type
        • 8.3.1.2.3. By End-user
    • 8.3.2. India Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By Molecule Type
        • 8.3.2.2.3. By End-user
    • 8.3.3. Japan Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By Molecule Type
        • 8.3.3.2.3. By End-user
    • 8.3.4. South Korea Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By Molecule Type
        • 8.3.4.2.3. By End-user
    • 8.3.5. Australia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By Molecule Type
        • 8.3.5.2.3. By End-user

9. Middle East & Africa Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Molecule Type
    • 9.2.3. By End-user
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By Molecule Type
        • 9.3.1.2.3. By End-user
    • 9.3.2. UAE Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By Molecule Type
        • 9.3.2.2.3. By End-user
    • 9.3.3. South Africa Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By Molecule Type
        • 9.3.3.2.3. By End-user

10. South America Fill-finish Pharmaceutical Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Molecule Type
    • 10.2.3. By End-user
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By Molecule Type
        • 10.3.1.2.3. By End-user
    • 10.3.2. Colombia Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By Molecule Type
        • 10.3.2.2.3. By End-user
    • 10.3.3. Argentina Fill-finish Pharmaceutical Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By Molecule Type
        • 10.3.3.2.3. By End-user

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Fill-finish Pharmaceutical Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Boehringer Ingelheim International GmbH
  • 15.3. Catalent Inc.
  • 15.4. Pfizer Inc.
  • 15.5. Baxter Pharmaceutical Solutions LLC
  • 15.6. Eurofins Scientific SE
  • 15.7. Symbiosis Pharma Pvt Ltd
  • 15.8. MabPlex International Co. Ltd.
  • 15.9. Fresenius Kabi Manufacturing
  • 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer